Mictamid 2.5% PAAG
is now Available to Licensed Veterinarians in the USA
Mictamid® is designed for the bulking of soft tissue. The product is composed of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water molecules, loosely bound to the polymer matrix. Mictamid® is a non-resorbable, injectable, transparent, hydrophilic gel. Mictamid® is biocompatible, non-biodegradable, and sterile. Upon injection, it forms a cushion-like, three-dimensional, stable structure. Vessel ingrowth begins immediately after injection into soft tissue. When Mictamid® is injected, macrophages respond to the foreign material, easily navigating the large pores. Soon after, the macrophages are replaced by fibroblasts and endothelial cells, which develop into a thin vessel-bearing fibrous network inside the gel. The gel is a permanent application, with no tissue hardening, disintegration, or migration. 2.5% PAAG is viscoelastic and has high water content, allowing constant molecular interaction. The lightly bound water molecules in the gel are easily interchanged with the surrounding tissue, facilitating the in-situ anchoring by the fibrous network and preventing the formation of a thick capsule. 2.5% Polyacrylamide Hydrogel- Mictamid® is a non-resorbable, injectable, transparent, hydrophilic gel. Mictamid® consists of a backbone of cross-linked polyacrylamide, with water molecules loosely bound to the polymer matrix. Nominal proportions of the Mictamid® gel are 2.5% cross-linked polyacrylamide and 97.5% nonpyrogenic water for injection. Mictamid® is biocompatible, nonbiodegradable, and sterile. Mictamid® adheres to the surrounding tissue through its ability to exchange water molecules. The gel becomes progressively integrated into its immediate surrounding tissue by a combination of cell migration and vessel ingrowth forming a thick, cushion-like membrane.
Contura-Vet is the animal division of Contura, operating in more than 25 countries, a company renowned for its hydrogels in human healthcare for facial reconstruction, urethral bulking, laryngoplasty, and intra-articular for the management of soft tissue conditions. All Contura products are manufactured in a European, FDA, GMP compliant facility.
Our hydrogels do not contain any additives, whether they be microparticles or products said to aid the anti-bacterial function of the gel, such as silver ions. In each case, our hydrogel is effective and safe without these additives.
Mictamid® is made up of 2.5% cross-linked polyacrylamide and 97.5% nonpyrogenic water.
2.5% PAAG is different from other described hydrogels that have different concentrations of polyacrylamide and may contain other components as well, e.g. silver ions. Furthermore, PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues — characteristics that ultimately determine the safety and effectiveness of each hydrogel.
Hydrogels are 3-dimensional, hydrophilic, polymeric networks capable of absorbing large amounts of water or biological fluids. Due to their high water content, porosity, and soft consistency, they closely simulate natural living tissue. In addition to biocompatibility, 2.5% PAAG is shown to be long-lasting and nondegradable.
2.5% PAAG has been studied for more than 30 years and found to be non-toxic, nonallergenic, nonteratogenic, nonembryotoxic, nonmutagenic, and nonbiodegradable. 2.5% PAAG has been proven safe in humans, horses, and dogs.
All studies are available by request.
Smith EA and Oehme FW. Acrylamide and poly- 114, No. 4 / BIOCOMPATIBILITY OF A NEW FILLER MATERIAL 941 acrylamide: A review of the production, use, environmental fate, and neurotoxicity. Rev Environ Health 9: 215, 1991. https://www.ncbi.nlm.nih.gov/pubmed/1668792
Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E, Ghisleni G, Paltrinieri S, Tunesi G, Nava M. Biocompatibility and tissue interactions of a new filler material for medical use Plast Reconstr Surg.2004 Sep 15;114(4):934-42 https://www.ncbi.nlm.nih.gov/pubmed/15468401
Lose G, Mouritsen L, Nielsen JB. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women BJU Int.2006 Jul;98(1):100-4 https://www.ncbi.nlm.nih.gov/pubmed/16831152
Narins RS and Schmidt R. Polyacrylamide hydrogel differences: Getting rid of the confusion. J Drugs Dermatol. 2011; 10(12): 1370-1375. https://jddonline.com/articles/dermatology/S1545961611P1370X/1/
Imke Janssen, Marc Koene, Christoph Lischer. Intraarticular application of polyacrylamide hydrogel as a treatment of osteoarthritis in the distal interphalangeal joint: case series with 12 horses. 2012 Nov 28;650-656 https://www.researchgate.net/publication/285966771_Intraarticular_applikation_of_polyacrylamide_hydrogel_as_a_treatment_of_osteoarthritis_in_the_distal_interphalangeal_joint_Case_series_with_12_horses
Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J Urol.2014 Sep;192(3):843-9 https://www.ncbi.nlm.nih.gov/pubmed/24704117
Tnibar A, Schougaard H, Camitz L, Rasmussen J, Koene M5, Jahn W, Markussen B. An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up. Acta Vet Scand. 2015 Apr 15;57:20 https://www.ncbi.nlm.nih.gov/pubmed/?term=An+international+multi-centre+prospective+study+on+the+efficacy+of+an+intraarticular+polyacrylamide+hydrogel+in+horses+with+osteoarthritis%3A+a+24+months+follow-up
Calo E and Khutoryanskiy VV. Biomedical applications of hydrogels: A review of patents and commercial products. Eur Polym J. 2015; 65: 252-267. https://www.sciencedirect.com/science/article/pii/S0014305714004091
Tnibar A, Persson AB, Jensen HE. Mechanisms of action of an intraarticular 2.5% polyacrylamide hydrogel (Arthramid Vet) in a goat model of osteoarthritis: Preliminary Observations. SM J Biomed Eng. 2017; 3: 1022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403890/
Vallejo A, Garcia-Ruano AA, Pinilla C, Castellano M, Deleyto E, Perez-Cano R. Comparing efficacy and costs of four facial fillers in HIV-associated lipodystrophy: a clinical trial
Plast Reconstr Surg.2017 Nov 8. https://www.ncbi.nlm.nih.gov/pubmed/29135895
De Clifford LT, Lowe JN, McKellar CD, Chambers M, David F. A single site, double-blinded, prospective study on the comparative efficacy of a 2.5% polyacrylamide hydrogel in horses with inter-carpal joint lameness. Equine Vet J; [Online] 2019. https://www.sciencedirect.com/science/article/abs/pii/S0737080618307615?dgcid=rss_sd_all
Midway KY 40347